{"nctId":"NCT03436693","briefTitle":"Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy","startDateStruct":{"date":"2018-02-15","type":"ACTUAL"},"conditions":["Diabetic Nephropathy"],"count":308,"armGroups":[{"label":"Canagliflozin 100mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Canagliflozin","otherNames":["TA-7284, Canaglu"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAdditional criteria check may apply for qualification:\n\n* Glycated hemoglobin(HbA1c) of ≥6.5% and ≤12.0%\n* eGFR of ≥30 mL/min/1.73m2 and \\<90 mL/min/1.73m2\n* The median UACR of the first morning void urine samples is ≥300 mg/g Cr and ≤5000 mg/g Cr\n* Patients who are taking on angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)\n* Patients who are under dietary management and taking therapeutic exercise for diabetes\n\nExclusion Criteria:\n\nAdditional criteria check may apply for qualification:\n\n* Type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes\n* A diagnosis of non-diabetic renal disease\n* Hereditary glucose-galactose malabsorption or primary renal glucosuria\n* Class IV heart failure symptoms according to New York Heart Association (NYHA) functional classification\n* Severe hepatic disorder or severe renal disorder\n* Blood potassium level \\>5.5 mmoL/L\n* Stable blood pressure (diastolic blood pressure (DBP) ≥100mmHg or systolic blood pressure (SBP) ≥180mmHg)","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104","description":"Percentage of participants with 30% decline in eGFR was calculated by multiple imputation method for missing data.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"29.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With 40% Decline in eGFR From Baseline at Week 104","description":"Percentage of participants with 40% decline in eGFR was calculated by multiple imputation method for missing data.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null},{"groupId":"OG001","value":"13.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in eGFR at Week 104","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.39","spread":"0.83"},{"groupId":"OG001","value":"-11.49","spread":"0.83"}]}]}]},{"type":"SECONDARY","title":"Composite Endpoint of End-stage Renal Disease (ESRD), Doubling of Serum Creatinine, Renal Death, and Cardiovascular (CV) Death","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.29","spread":null},{"groupId":"OG001","value":"38.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Percentage of Urine Albumin-to -Creatinine Ratio (UACR) at Week 104","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.612","spread":null},{"groupId":"OG001","value":"1.178","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":43,"n":154},"commonTop":["Nasopharyngitis","Hypoglycaemia","Blood glucose decreased","Back pain","Constipation"]}}}